CIK 0001604821 · Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 010894487
- Phone
- 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −800 | $393.47 | $315K | 2,166,694 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −300 | $394.40 | $118K | 2,166,394 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,900 | $396.30 | $753K | 2,164,494 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,100 | $397.16 | $437K | 2,163,394 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −600 | $398.09 | $239K | 2,162,794 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −793 | $399.31 | $317K | 2,162,001 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,671 | $400.31 | $1.1M | 2,159,330 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −5,974 | $401.42 | $2.4M | 2,153,356 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,309 | $402.23 | $2.5M | 2,147,047 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,858 | $403.27 | $1.6M | 2,143,189 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −10,321 | $404.64 | $4.2M | 2,132,868 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −6,274 | $405.18 | $2.5M | 2,126,594 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,400 | $406.63 | $569K | 2,125,194 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −3,800 | $407.27 | $1.5M | 2,121,394 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −2,000 | $408.24 | $816K | 2,119,394 |
| 2026-10-15 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Option exercise · Stock Option (right to buy) 10b5-1 | −50,000 | 0 | ||
| 2026-10-07 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Gift | −6,000 | 2,119,394 | ||
| 2026-10-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −200 | $411.62 | $82K | 109,714 |
| 2026-10-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −954 | $413.11 | $394K | 108,760 |
| 2026-10-01 | Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS | Sale 10b5-1 | −1,846 | $415.07 | $766K | 106,914 |
Page 6 of 39 · 767 trades